National Center for International Research of Biological Targeting Diagnosis and Therapy, Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Guangxi 530021, China.
Department of Theracic Surgery, Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, China.
Theranostics. 2017 Oct 17;7(19):4862-4876. doi: 10.7150/thno.19101. eCollection 2017.
Tumor vessels can potentially serve as diagnostic, prognostic and therapeutic targets for solid tumors. Fluorescent dyes are commonly used as biological indicators, while photobleaching seriously hinders their application. In this study, we aim to generate a fluorescent silica nanoparticles (FSiNPs) theranostic system marked by the mouse endgolin (mEND) aptamer, YQ26. : A highly specific YQ26 was selected by using gene-modified cell line-based SELEX technique. FSiNPs were prepared via the reverse microemulsion method. The YQ26-FSiNPs theranostic system was developed by combining YQ26 with the FSiNPs for tumor imaging, treatment and monitoring. : Both experiments (i.e. cellular and tumor tissue targeting assays) and animal studies (i.e. imaging and antitumor efficacy of YQ26-FSiNPs) clearly demonstrated that YQ26-FSiNPs could achieve prominently high targeting efficiency and therapeutic effects via aptamer YQ26-mediated binding to endoglin (END) molecule. : This simple, sensitive, and specific YQ26-FSiNPs theranostic system has a great potential for clinical tumor targeting imaging and treatment.
肿瘤血管可以作为实体瘤的诊断、预后和治疗靶点。荧光染料通常被用作生物标志物，而光漂白严重阻碍了它们的应用。在这项研究中，我们旨在生成一种荧光硅纳米颗粒（FSiNPs）治疗系统，该系统由小鼠内皮糖蛋白（mEND）适体 YQ26 标记：通过基于基因修饰细胞系的 SELEX 技术，筛选出一种高度特异性的 YQ26。通过反相微乳液法制备 FSiNPs。通过将 YQ26 与 FSiNPs 结合，开发了 YQ26-FSiNPs 治疗系统，用于肿瘤成像、治疗和监测。：细胞和肿瘤组织靶向实验以及动物研究（即 YQ26-FSiNPs 的成像和抗肿瘤疗效）均清楚地表明，YQ26-FSiNPs 可以通过适体 YQ26 与内皮糖蛋白（END）分子的结合，实现明显的高靶向效率和治疗效果。：这种简单、灵敏、特异的 YQ26-FSiNPs 治疗系统具有很大的临床肿瘤靶向成像和治疗的潜力。
